tiprankstipranks
Trending News
More News >
PAVmed Inc (PAVM)
NASDAQ:PAVM
US Market
Advertisement

PAVmed (PAVM) AI Stock Analysis

Compare
534 Followers

Top Page

PAVM

PAVmed

(NASDAQ:PAVM)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
$0.50
▲(13.64% Upside)
PAVmed's overall stock score is primarily impacted by its poor financial performance, characterized by significant profitability and liquidity challenges. The technical analysis suggests a bearish trend, while the valuation indicates potential undervaluation but is overshadowed by the company's financial struggles.
Positive Factors
Innovative Product Portfolio
PAVmed's focus on innovative medical devices addressing unmet clinical needs positions it well in the healthcare sector, potentially driving long-term growth as these products gain adoption.
Revenue Model
The company's diverse revenue model, including direct sales and potential licensing agreements, enhances its ability to generate stable income streams and leverage partnerships for market expansion.
Equity Ratio
A high equity ratio indicates a strong capital structure, providing PAVmed with a solid foundation to support its operations and future growth initiatives.
Negative Factors
Negative Margins
Severe negative margins highlight significant profitability issues, indicating operational inefficiencies that could hinder long-term financial stability and growth.
Cash Flow Challenges
Negative cash flow ratios suggest liquidity challenges, limiting PAVmed's ability to reinvest in its business and potentially affecting its capacity to sustain operations without external financing.
Return on Equity
A deeply negative ROE indicates that the company is not generating sufficient returns on shareholders' equity, which could deter investment and impact long-term shareholder value.

PAVmed (PAVM) vs. SPDR S&P 500 ETF (SPY)

PAVmed Business Overview & Revenue Model

Company DescriptionPAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
How the Company Makes MoneyPAVmed generates revenue through the sales of its medical devices and diagnostic products to hospitals, clinics, and healthcare providers. The company's revenue model is primarily based on direct sales and distribution agreements, allowing it to reach a wide range of customers. Key revenue streams include product sales from its innovative devices, potential licensing agreements, and partnerships with healthcare organizations that facilitate the adoption of its technologies. Additionally, PAVmed may benefit from reimbursement policies for its products, which can enhance sales and overall revenue growth.

PAVmed Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q1-2025)
|
% Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook, focusing on strengthened financial positions, operational milestones, and upcoming advancements with Veris Health. However, some challenges remain, such as pending Medicare coverage and financial adjustments due to deconsolidation. Overall, the positive aspects outweighed the challenges.
Q1-2025 Updates
Positive Updates
Strengthened Financial Position
PAVmed significantly strengthened its balance sheet with an underwritten public offering netting $16.1 million, bolstering the balance sheet. Lucid had $40 million in pro forma cash at the end of Q1, extending the runway well into 2026.
Operational Milestones and Advancements
Lucid reported revenue of $800,000 in the last quarter with a test volume of 3,034, at the upper end of the target range of 2,500 to 3,000 tests per quarter. The company is also making progress with new sales channels, including concierge medicine and employer market contracts.
Veris Health Developments
Veris Health has secured financing to restart the development of a critical implantable monitor, with a favorable engagement with the FDA. The company expects to file with the FDA in the first half of 2026.
Positive Financial Metrics
PAVmed showed a large GAAP net income of $18.6 million before NCI and preferred dividends, resulting in a GAAP positive primary EPS of $1.28 per share and a positive diluted EPS of $0.34 per share.
Negative Updates
Pending Medicare Coverage
PAVmed is still awaiting a response from the MolDX program regarding Medicare coverage for its e-cigar product, which is crucial for future growth.
Operational and Financial Adjustments
The company is undergoing significant changes in financial reporting due to the deconsolidation of Lucid, which could create some confusion in understanding historical financial information.
Company Guidance
During the PAVmed's First Quarter 2025 Business Update Conference Call, key guidance metrics were highlighted, focusing on the company's strategic positioning and financial status. Lucid Diagnostics, PAVmed's publicly traded subsidiary, reported Q1 revenue of $800,000 with a test volume of 3,034, within their target range of 2,500 to 3,000 tests per quarter. Lucid also enhanced its financial position with a netting of $16.1 million from a public offering, boosting its pro forma cash to $40 million, extending its runway into 2026. PAVmed's CEO, Dr. Lishan Aklog, emphasized Lucid's progress toward securing Medicare coverage and expanding sales channels, particularly in concierge medicine and employer markets. Meanwhile, Veris Health, PAVmed's digital health subsidiary, resumed the development of its implantable monitor, with an FDA filing expected in the first half of 2026. Financially, PAVmed reported a non-GAAP loss of $910,000 for Q1, with operating expenses of approximately $5.4 million, and significant balance sheet improvements were noted, including a $25 million liability reduction.

PAVmed Financial Statement Overview

Summary
PAVmed faces significant financial challenges, particularly in terms of profitability and cash flow management. Despite revenue growth, the company struggles with negative margins and returns, indicating operational inefficiencies and potential liquidity risks.
Income Statement
15
Very Negative
PAVmed's income statement reveals significant challenges. The company has experienced substantial negative margins across all key metrics, including gross profit, net profit, EBIT, and EBITDA. Despite a notable revenue growth rate of 251.93% in the TTM period, the negative margins indicate severe profitability issues, with a net profit margin of -1885.26% and a gross profit margin of -5.06%. These figures suggest that the company is struggling to convert its revenue into profit, highlighting a critical need for operational improvements.
Balance Sheet
20
Very Negative
The balance sheet shows a mixed picture. While the debt-to-equity ratio is relatively low at 0.25, indicating manageable leverage, the return on equity is deeply negative at -140.79%, reflecting significant losses relative to shareholder equity. The equity ratio stands at 85.47%, suggesting a strong equity base relative to total assets. However, the negative ROE and historical equity deficits raise concerns about the company's ability to generate returns for shareholders.
Cash Flow
25
Negative
PAVmed's cash flow statement indicates some positive trends, such as a free cash flow growth rate of 72.83% in the TTM period. However, the operating cash flow to net income ratio is negative, and the free cash flow to net income ratio is slightly above 1, suggesting that the company is not effectively converting its net income into cash flow. The negative operating cash flow coverage ratio further underscores liquidity challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.01M3.00M2.45M377.00K500.00K0.00
Gross Profit-35.49M-3.04M-3.97M-3.24M-85.00K-23.00K
EBITDA-4.63B29.67M-75.74M-99.41M-55.90M-35.81M
Net Income72.88M39.79M-64.17M-88.98M-50.35M-34.33M
Balance Sheet
Total Assets43.89M30.66M33.12M53.98M86.98M19.78M
Cash, Cash Equivalents and Short-Term Investments4.00B1.19M19.64M39.74M77.26M17.26M
Total Debt9.31B31.86M48.73M36.64M0.0014.96M
Total Liabilities12.47M37.69M57.14M43.05M7.56M20.25M
Stockholders Equity40.79M-2.50M-53.83M-9.68M61.67M1.90M
Cash Flow
Free Cash Flow-2.77B-33.61M-52.28M-72.53M-42.06M-21.97M
Operating Cash Flow-2.77B-33.55M-52.04M-70.98M-40.59M-21.91M
Investing Cash Flow-24.14M-16.18M758.00K-4.74M-3.72M-55.00K
Financing Cash Flow2.49B31.28M31.17M38.21M104.31M33.01M

PAVmed Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.44
Price Trends
50DMA
0.47
Negative
100DMA
0.54
Negative
200DMA
0.62
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
49.33
Neutral
STOCH
56.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Positive. The current price of 0.44 is above the 20-day moving average (MA) of 0.43, below the 50-day MA of 0.47, and below the 200-day MA of 0.62, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.33 is Neutral, neither overbought nor oversold. The STOCH value of 56.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PAVM.

PAVmed Risk Analysis

PAVmed disclosed 54 risk factors in its most recent earnings report. PAVmed reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

PAVmed Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
49
Neutral
$10.85M-0.74-202.86%0.36%-17.20%
49
Neutral
$10.83M-0.20-228.99%-12.60%95.87%
45
Neutral
$17.09M-0.32-69.30%-91.14%9.47%
45
Neutral
$9.45M-0.44-4272.16%-66.40%65.99%
44
Neutral
$9.51M0.38-499.57%-73.36%
40
Underperform
$7.92M-1.28-121.14%-1.88%23.99%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PAVM
PAVmed
0.44
-0.86
-66.15%
SSKN
Strata Skin Sciences
2.07
-0.53
-20.38%
BMRA
Biomerica
2.76
0.12
4.55%
CODX
Co-Diagnostics
0.35
-0.85
-70.83%
TNON
Tenon Medical, Inc.
1.22
-2.89
-70.32%
HSCS
Heart Test Laboratories, Inc.
3.69
-0.70
-15.95%

PAVmed Corporate Events

Private Placements and Financing
PAVmed’s Lucid Diagnostics Completes Public Stock Offering
Neutral
Sep 11, 2025

On September 11, 2025, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., completed a public offering of 28,750,000 shares of its common stock at $1.00 per share, raising approximately $26.9 million after expenses. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.

The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
PAVmed Reports Q2 2025 Financial Results and Developments
Neutral
Aug 14, 2025

In its second quarter of 2025, PAVmed Inc. reported significant business developments and financial results. Lucid Diagnostics processed 2,756 EsoGuard tests, generating $1.2 million in revenue, and secured a Medicare LCD meeting for September 4, 2025. Veris Health completed financing and is advancing its implantable monitor towards FDA clearance, with strategic partnerships in place to enhance its commercial deployment. PAVmed’s financial results showed a GAAP net loss of $13.3 million, with a strengthened balance sheet and cash reserves of $4.0 million as of June 30, 2025.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
PAVmed Granted Nasdaq Extension for Compliance
Neutral
Jul 30, 2025

On July 29, 2025, PAVmed Inc. received a notification from Nasdaq granting an additional 180 days, until January 19, 2026, to comply with the minimum bid price requirement of $1 per share. The company had initially been given until July 22, 2025, to meet this requirement but failed to do so. Despite this, Nasdaq has allowed an extension, and PAVmed plans to explore all options to regain compliance. The company’s stock will continue to trade under the symbol ‘PAVM’ without interruption.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
PAVmed’s Veris Health Completes $2.5M Offering
Positive
Jun 24, 2025

On June 23, 2025, Veris Health Inc., a subsidiary of PAVmed Inc., completed a $2.5 million offering by selling shares and warrants to accredited investors, aimed at funding the development of its implantable physiological monitor and general operations. This strategic move enhances Veris’ financial position and provides investors with future participation rights, potentially strengthening its market presence and operational capabilities.

The most recent analyst rating on (PAVM) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Shareholder Meetings
PAVmed Holds Annual Stockholders Meeting, Approves Key Proposals
Neutral
Jun 18, 2025

On June 18, 2025, PAVmed Inc. held its annual meeting of stockholders, where approximately 77.2% of shares were represented. During the meeting, stockholders elected management’s nominees for director, approved the issuance of common stock upon exercise of pre-funded warrants, amended the 2014 Long-Term Incentive Equity Plan to increase available shares, approved executive compensation, and ratified the appointment of Marcum LLP as the independent registered certified public accounting firm for 2025.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 02, 2025